1Lahuerta J J, Mateos MV, Martinez-L6pez J, et al. Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival[J]. J Clin Oncol, 2008, 26(35 ): 5775-5782.
2Eom HS, Min CK, Cho BS, et al. Retrospective comparison ofbortezomib-containing regimens with vincristine-doxorubicin- dexamethasone (VAD) as induction treatment prior to autolo- gous stem cell transplantation for multiple myeloma ~J~. Jpn J Clin Oncol, 2009, 39(7): 449-455.
3Harousseau JL, Attal M, Avet-Loiseau H, et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem- cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial [Jl. J Clin Oncol, 2010, 28(30): 4621-4629.
4Jakubowiak AJ, Kendall T, A1-Zoubi A, et al. Phase II trial of combination therapy with bortezomib, pegylated liposomal doxorubicin, and dexamethasone in patients with newly diagnosed myeloma [ J 1. J Clin Oncol, 2009, 27 ( 30): 5015 -5022.
7Blad6 J, SamsonD, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant [J~. Br J Haematol, 1998, 102(5): 1115-1123.
9Petrucci MT, Giraldo P, Corradini P, et al. A prospective, interna- tional phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma [J].Br J Haematol, 2013, 160 (5): 649-659.
10Popat R, Oakervee HE, Hallam S, et al. Bortezomib, doxorubi- cin and dexamethasone (PAD) front-line treatment of multiple myeloma: updated results after long- term follow- up [J]. Br J Haematol, 2008, 141(4): 512-516.
二级参考文献21
1Kyle RA,Leong T,Li S, et al. Complete response in multiple myeloma: clinical trial E9486, an Eastern Cooperative Oncology Group study not involving stem cell transplantation. Cancer,2006, 106 : 1958-1966.
2Sundar J, Brian G, Jeffrey W, et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol, 2005,129: 776- 783.
3Segeren CM, Sonneveld P, van der Holt B, et al. Vincristine, doxorubicin and dexamethasone (VAD) administered as rapid intravenous infusion for first-line treatment in untreated multiple myeloma. Br J Haematol, 1999,105:127-130.
4Blade J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol, 1998,102: 1115- 1123.
5Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med, 2003, 348: 1875-1883.
6OShea D, Giles C, Terpos E, et al. Predictive factors for survival in myeloma patients who undergo autologous stem cell transplanta- tion: a single-centre experience in 211 patients. Bone Marrow Transplant, 2006,37:731-737.
7Harousseau JL, Attal M, Leleu X, et al. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: Resuits of an IFM phase II study. Haematologica, 2006,1:1498- 1505.
8San Miguel JF, Blade Creixenti J, Garcia-Sanz R. Treatment of multiple myeloma. Haematologica, 1999,84 : 36-58.
9Sirohi B, Powles R, Kulkarni S, et al. Comparison of new patients with Bence-Jones, IgG and IgA myeloma receiving sequential therapy: the need to regard these immunologic subtypes as separate disease entities with specific prognostic criteria. Bone Marrow Transplant. 2001. 28 :29- 37.
10Knudsen LM, Hjorth M, Hippe E. Renal failure in multiple myeloma: reversibility and impact on the prognosis. Eur J Hematol, 2000. 65 : 175-181.
